<< Back to Corporate Member News

FDA approves KADCYLA™ for HER2+ metastatic breast cancer

Genentech is excited to share the news of a new FDA approval for HER2+ metastatic breast cancer: KADCYLA™ (ado-trastuzumab emtansine).

KADCYLA™ (ado-trastuzumab emtansine) injection, for intravenous use, as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.